The company said that sales range reflects a decision to halt shipments of Gardasil, a vaccine that prevents cancer from HPV, ...

Gardasil 9 is the only HPV vaccine used in the U.S., and it’s also one of the only vaccines on the market that actually prevents cancer. That’s because HPV is behind nearly all cervical cancer cases ...

NEW YORK, NY / ACCESS Newswire / April 6, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...

(Bloomberg) -- Merck & Co.’s blockbuster vaccine Gardasil has had a roller-coaster ride in China. A post-Covid surge in ...

GARDASIL 9 is a vaccine that helps protect against disease caused by the following types of Human Papillomavirus (HPV): 6, 11, 16, 18, 31, 33, 45, 52 and 58. For more information, see Section 1.

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Merck & Co., Inc. ("Merck" or the "Company") (NYSE: MRK) and reminds investors of the April 14, ...

United States-based global pharmaceutical company MSD said on Monday that China's National Medical Products Administration has approved the use of multiple new indications of Gardasil®9, its ...

Multinational companies in China’s vaccine market face headwinds amid an anti-corruption crackdown and rising competition.

MSD has opened the doors of a $1 billion manufacturing facility at its site in Durham, North Carolina, that will be used to produce the bulk drug substance for its HPV vaccine Gardasil.

On July 30, 2024, Merck released its second quarter 2024 financial report and disclosed a significant reduction in Gardasil vaccinations, resulting in an overabundance of inventory at Merck's Chinese ...

Shares fell more than 10% as Merck paused Gardasil shipments to China, and 2025 sales guidance of $64.1 billion-$65.6 billion implies flat to 2% growth. Merck's Keytruda Dominance and a Strong ...

In its Q2 2024 earnings, MSD announced that sales for Gardasil were 17% lower (18% in exchange) compared to the previous year. At the time, the company attributed this to broader market headwinds ...